$PKTX
ProtoKinetix, Inc.

2023 Q2 Form 10-Q Financial Statement

#000107997323000595 Filed on May 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $72.03K $73.66K $347.7K
YoY Change -78.72% -78.81% 282.0%
% of Gross Profit
Research & Development $31.98K $22.68K $163.1K
YoY Change -68.93% -86.09% 294.7%
% of Gross Profit
Depreciation & Amortization $11.57K $10.70K $750.00
YoY Change 1442.67% 1326.67% 0.0%
% of Gross Profit
Operating Expenses $115.6K $107.0K $511.5K
YoY Change -73.86% -79.07% 284.35%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$115.6K -$107.0K -$511.5K
YoY Change -73.86% -79.07% 284.35%
Income Tax
% Of Pretax Income
Net Earnings -$115.6K -$107.0K -$511.5K
YoY Change -126.14% -79.07% 284.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share $0.00 $0.00 -$1.785K
COMMON SHARES
Basic Shares Outstanding 327.9M shares 325.5M shares
Diluted Shares Outstanding 335.6M shares 325.5M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.66K $6.940K $58.88K
YoY Change -0.9% -88.21% -76.48%
Cash & Equivalents $18.66K $6.942K $57.88K
Short-Term Investments
Other Short-Term Assets $1.050K $1.050K $1.050K
YoY Change 0.0% 0.0% 0.0%
Inventory
Prepaid Expenses $1.050K $1.050K
Receivables
Other Receivables
Total Short-Term Assets $19.71K $7.992K $59.93K
YoY Change -0.86% -86.66% -76.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $447.3K $439.3K $367.5K
YoY Change 13.76% 19.54% 18.93%
TOTAL ASSETS
Total Short-Term Assets $19.71K $7.992K $59.93K
Total Long-Term Assets $447.3K $439.3K $367.5K
Total Assets $467.0K $447.3K $427.4K
YoY Change 13.06% 4.65% -23.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.26K $53.00K $7.000K
YoY Change -63.95% 657.14% 40.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.26K $53.00K $7.000K
YoY Change -63.95% 657.14% 40.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.26K $53.00K $7.000K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $13.26K $53.00K $7.000K
YoY Change -63.95% 657.14% 40.0%
SHAREHOLDERS EQUITY
Retained Earnings -$47.67M -$47.56M
YoY Change 2.53%
Common Stock $1.795K $1.747K
YoY Change 9.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $453.7K $394.3K $426.6K
YoY Change
Total Liabilities & Shareholders Equity $467.0K $447.3K $427.4K
YoY Change 13.06% 4.65% -23.73%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$115.6K -$107.0K -$511.5K
YoY Change -126.14% -79.07% 284.35%
Depreciation, Depletion And Amortization $11.57K $10.70K $750.00
YoY Change 1442.67% 1326.67% 0.0%
Cash From Operating Activities -$143.8K -$84.87K -$336.3K
YoY Change -12.15% -74.77% 116.96%
INVESTING ACTIVITIES
Capital Expenditures $19.53K $13.74K -$5.580K
YoY Change -173.95% -346.24% -84.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$19.53K -$13.74K -$5.580K
YoY Change -26.05% 146.29% -84.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $80.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 175.0K $80.00K 343.2K
YoY Change 16.67% -76.69% 38.95%
NET CHANGE
Cash From Operating Activities -143.8K -$84.87K -336.3K
Cash From Investing Activities -19.53K -$13.74K -5.580K
Cash From Financing Activities 175.0K $80.00K 343.2K
Net Change In Cash 11.72K -$18.61K 1.310K
YoY Change -129.26% -1520.46% -97.7%
FREE CASH FLOW
Cash From Operating Activities -$143.8K -$84.87K -$336.3K
Capital Expenditures $19.53K $13.74K -$5.580K
Free Cash Flow -$163.3K -$98.61K -$330.7K
YoY Change 18.98% -70.19% 175.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1050 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
7992 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
26600 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
439310 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
436270 usd
CY2023Q1 us-gaap Assets
Assets
447302 usd
CY2022Q4 us-gaap Assets
Assets
462870 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
53000 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001128189
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-32917
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
PROTOKINETIX, INCORPORATED
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3355026
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
109 W Main St.
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dalton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
44618
CY2023Q1 dei City Area Code
CityAreaCode
740
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
434-5041
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
327880151 shares
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6942 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
25550 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1050 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
41530 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
53000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
41530 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000053
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000053
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
326880151 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
326880151 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
322880151 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
322880151 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1747 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1726 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47948072 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47868093 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47555517 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47448479 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
394302 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
421340 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
447302 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462870 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10703 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
750 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32763 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64187 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
40893 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
47753 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22679 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
163049 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
241853 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
107038 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
517592 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-107038 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-517592 usd
CY2023Q1 PKTX Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.01
CY2022Q1 PKTX Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.01
CY2023Q1 PKTX Weighted Average Number Of Common Shares Outstanding Basic And Diluted
WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
325457929 shares
CY2022Q1 PKTX Weighted Average Number Of Common Shares Outstanding Basic And Diluted
WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
299216892 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
421340 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
80000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-107038 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
394302 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
352966 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
343200 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
241853 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-517592 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
420427 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-107038 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-517592 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10703 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
750 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
241853 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-24945 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11470 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-86268 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84865 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-336312 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
13743 usd
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5577 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13743 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5577 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
343200 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
343200 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18608 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1311 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25550 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57568 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6942 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57879 usd
CY2015 PKTX Payment To Acquire Intangible Assets
PaymentToAcquireIntangibleAssets
30000 usd
CY2015Q4 PKTX Additional Patent Applications
AdditionalPatentApplications
10000 usd
CY2015 PKTX Warrant Issued
WarrantIssued
6000000 shares
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
25000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
514220 usd
CY2023Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
13743 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zmpFeTTxmgn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_866_zHYuWWc19Pbh">Use of Estimates</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to valuation of equity related instruments issued, deferred income taxes, and the useful life and impairment of intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023Q1 us-gaap Deposits Assets
DepositsAssets
1050 usd
CY2022Q4 us-gaap Deposits Assets
DepositsAssets
1050 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
382171 usd
CY2022 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
132049 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
527963 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19500 usd
CY2022 PKTX Amortization
Amortization
3000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
77950 usd
CY2023Q1 PKTX Amortization
Amortization
10703 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
88653 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
436270 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
439310 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10703 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
750 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
13743 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
241853 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
94290000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
94290000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13300000 shares
CY2023Q1 PKTX Common Stock Shares Authorizeds
CommonStockSharesAuthorizeds
500000000 shares
CY2022Q4 PKTX Common Stock Shares Authorizeds
CommonStockSharesAuthorizeds
500000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000053
CY2023Q1 us-gaap Dividends Receivable
DividendsReceivable
0 usd
CY2022Q4 us-gaap Dividends Receivable
DividendsReceivable
0 usd
CY2023Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
15000 usd
CY2022Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
15000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
5250000 shares
CY2023Q1 PKTX Due To Related Parties Currents
DueToRelatedPartiesCurrents
0 usd
CY2022Q1 PKTX Due To Related Parties Currents
DueToRelatedPartiesCurrents
0 usd

Files In Submission

Name View Source Status
0001079973-23-000595-index-headers.html Edgar Link pending
0001079973-23-000595-index.html Edgar Link pending
0001079973-23-000595.txt Edgar Link pending
0001079973-23-000595-xbrl.zip Edgar Link pending
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pktx-20230331.xsd Edgar Link pending
pktx_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
pktx-20230331_cal.xml Edgar Link unprocessable
pktx-20230331_lab.xml Edgar Link unprocessable
pktx-20230331_pre.xml Edgar Link unprocessable
pktx-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pktx_10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending